{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["49(9)"],"submitter":["Katoh N"],"funding":["Sanofi K.K.","Sanofi and Regeneron Pharmaceuticals, Inc."],"pubmed_abstract":["Atopic dermatitis (AD), a chronic relapsing inflammatory skin disease with a high disease burden, is one of the most common dermatological conditions in Japan. Herein, we report the disease profiles and current AD treatment during 2-year management of Japanese adults with moderate-to-severe AD. ADDRESS-J was a prospective, longitudinal, observational study that evaluated real-world effectiveness and safety of current AD treatments of adult patients with moderate-to-severe AD (Investigator's Global Assessment score 3 or 4) in Japan. The maximum follow-up period was 2 years. Among 300 patients enrolled, 288 had ≥1 post-baseline evaluation and were analyzed (mean age, 35.5 years; 60.1% male). Almost all patients (99.7%) received topical therapy; the most commonly used therapy was topical cort"],"journal":["The Journal of dermatology"],"pagination":["903-911"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9543354"],"repository":["biostudies-literature"],"pubmed_title":["Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate-to-severe atopic dermatitis: Two-year data from the ADDRESS-J disease registry."],"pmcid":["PMC9543354"],"pubmed_authors":["Saeki H","Teramukai S","Takagi H","Katoh N","Ardeleanu M","Etoh T","Fujita H","Rizova E","Kataoka Y","ADDRESS-J Investigators","Arima K"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate-to-severe atopic dermatitis: Two-year data from the ADDRESS-J disease registry.","description":"Atopic dermatitis (AD), a chronic relapsing inflammatory skin disease with a high disease burden, is one of the most common dermatological conditions in Japan. Herein, we report the disease profiles and current AD treatment during 2-year management of Japanese adults with moderate-to-severe AD. ADDRESS-J was a prospective, longitudinal, observational study that evaluated real-world effectiveness and safety of current AD treatments of adult patients with moderate-to-severe AD (Investigator's Global Assessment score 3 or 4) in Japan. The maximum follow-up period was 2 years. Among 300 patients enrolled, 288 had ≥1 post-baseline evaluation and were analyzed (mean age, 35.5 years; 60.1% male). Almost all patients (99.7%) received topical therapy; the most commonly used therapy was topical cort","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-22T12:08:18.99Z","creation":"2025-04-06T00:12:53.924Z"},"accession":"S-EPMC9543354","cross_references":{"pubmed":["35715964"],"doi":["10.1111/1346-8138.16485"]}}